Ketamine Shows Promise for Chronic Fatigue Relief

Millions of Americans living with debilitating chronic fatigue may finally have a new treatment option on the horizon, thanks to promising research from Rutgers Health and the National Institutes of Health.

Scientists tested ketamine, a medication already approved for severe depression, on 10 participants suffering from chronic fatigue linked to cancer recovery, fibromyalgia, lupus, and chronic fatigue syndrome. The results surprised even the researchers.

After a single low-dose infusion, participants experienced nearly a 39% drop in fatigue levels within 24 hours. Three days later, fatigue scores remained 21% lower than before treatment.

This matters because chronic fatigue affects an estimated 3.3 million American adults, leaving them too exhausted for work, family activities, or basic daily tasks. No amount of rest helps, and most people who complete cancer treatment develop it for a year or longer.

"Fatigue has always been ignored because it's so difficult to understand what's causing it," says study senior author Leorey Saligan, a professor at Rutgers School of Nursing. For years, doctors have recommended exercise as the main treatment, but most patients lack the energy to even start a program.

The study started when Saligan's earlier research discovered that certain brain receptors predicted chronic fatigue in cancer survivors. Since ketamine blocks these same receptors, testing it made perfect sense.

The researchers didn't expect ketamine to be a permanent solution. Instead, they envision it as a bridge treatment that gives patients enough energy to begin exercise programs and other therapies proven to provide lasting relief.

Why This Inspires

This research represents hope for a condition that medicine has largely ignored or misunderstood for decades. While the study was small and the results weren't dramatic compared to the placebo, even a minor breakthrough matters when nothing else has worked.

Ketamine is already off-patent and widely studied, meaning drug companies are developing newer versions with fewer side effects. A nasal spray version exists for depression, opening doors for easier chronic fatigue treatment if larger trials succeed.

Saligan is now preparing a bigger clinical trial specifically for breast cancer survivors. The goal is to confirm whether ketamine can truly reset the brain enough to motivate people into sustainable recovery strategies.

For patients who've spent years too tired to live their lives, even the possibility of a short energy boost represents genuine progress worth celebrating.